European Union - English - EMA (European Medicines Agency)

amgen technology (ireland) uc - eculizumab - hemoglobinuria, paroxysmal - immunosuppressants - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1).

European Union - English - EMA (European Medicines Agency)

amgen technology (ireland) uc - bevacizumab - carcinoma, renal cell; peritoneal neoplasms; ovarian neoplasms; breast neoplasms; carcinoma, non-small-cell lung; fallopian tube neoplasms - antineoplastic agents - mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. for further information as to human epidermal growth factor receptor 2 (her2) status, please refer to section 5.1.mvasi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer.mvasi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iiib, iiic and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer.mvasi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor-targeted agents.mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor-targeted agents.mvasi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

amgen technology (ireland) uc - bevacizumab - bevacizumab....25 mg

Singapore - English - HSA (Health Sciences Authority)

amgen biotechnology singapore pte ltd - adalimumab - injection, solution - adalimumab 40mg/0.8ml

Singapore - English - HSA (Health Sciences Authority)

amgen biotechnology singapore pte ltd - adalimumab - injection, solution - adalimumab 20 mg/0.4 ml

Singapore - English - HSA (Health Sciences Authority)

amgen biotechnology singapore pte ltd - adalimumab - injection, solution - adalimumab 40 mg/0.8 ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

amgen technology ireland, ireland - bevacizumab - concentrate for solution for infusion - 25 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

amgen technology ireland, ireland - bevacizumab - concentrate for solution for infusion - 25 mg/ml

Singapore - English - HSA (Health Sciences Authority)

amgen biotechnology singapore pte ltd - trastuzumab - injection, powder, for solution - trastuzumab 150mg/vial

Singapore - English - HSA (Health Sciences Authority)

amgen biotechnology singapore pte ltd - trastuzumab - injection, powder, for solution - trastuzumab 440mg/vial